Omega Therapeutics Overview
- Founded
- 2017
- Status
- Private
- Employees
- 55
- Latest Deal Type
- Series C
- Latest Deal Amount
- $126M
- Investors
- 8
Omega Therapeutics General Information
Description
Developer of transformative precision therapeutics designed to deliver effective and safe therapies that modulate gene expression. The company's therapeutics focus on selectively directing the human genome to treat and cure disease by precisely controlling genomic expression for a range of disease indications including rare genetic diseases, immunology, inflammation, metabolic diseases and oncology, enabling doctors to treat and cure diseases without altering a patient's native genomic nucleic acid code.
Contact Information
Website
Formerly Known As
VL42
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
- 20 Acorn Park Drive
- Cambridge, MA 02140
- United States
+1 (617) 000-0000
Omega Therapeutics Timeline
Omega Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 30-Mar-2021 | $126M | 00000 | 00000 | Completed | Generating Revenue |
| 3. Later Stage VC (Series B) | 29-Jul-2020 | 0000 | 00000 | 00000 | Completed | Startup |
| 2. Debt - General | 09-Mar-2018 | $8M | $33M | Completed | Startup | |
| 1. Later Stage VC (Series A) | 01-May-2017 | $25M | $25M | 0000 | Completed | Startup |
Omega Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00.000 | |
| Series B | 00,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 00.000 | |
| Series A | 57,125,232 | $0.001000 | $0.5 | $0.5 | 1x | $0.5 | 36% |
Omega Therapeutics Executive Team (9)
Omega Therapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Berry Ph.D | Self | Co-Founder & Board Member | 000 0000 |
| John Mendlein Ph.D | Flagship Pioneering | Board Member | 000 0000 |
| Mahesh Karande | Omega Therapeutics | President, Chief Executive Officer & Board Member | 000 0000 |
| Mary Szela | Self | Board Member | 000 0000 |
| Noubar Afeyan Ph.D | Self | Co-Founder & Chairman | 000 0000 |
Omega Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialOmega Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| BlackRock | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Cowen and Company | Investment Bank | Minority | 000 0000 | 000000 0 | |
| Fidelity Management & Research | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Logos Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Mirae Asset Capital | Other | Minority | 000 0000 | 000000 0 |